NCT00095563View on ClinicalTrials.gov

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2009

Study Completion Date

June 30, 2009

Conditions
High-grade Salivary Gland CarcinomaHigh-grade Salivary Gland Mucoepidermoid CarcinomaLow-grade Salivary Gland CarcinomaLow-grade Salivary Gland Mucoepidermoid CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Salivary Gland CancerSalivary Gland Acinic Cell TumorSalivary Gland AdenocarcinomaSalivary Gland Adenoid Cystic CarcinomaSalivary Gland Malignant Mixed Cell Type Tumor
Interventions
DRUG

lapatinib ditosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00095563 - Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | Biotech Hunter | Biotech Hunter